Rituximab: check for low gammaglobulins say researchers

In the US, despite recommendations, screening is rare

Patients being considered for rituximab therapy should be checked for low gammaglobulin levels before and after the therapy is given, researchers report.

Several reports have described prolonged hypogammaglobulinaemia and associated infections in patients receiving rituximab, a monoclonal antibody that depletes CD20-expressing B cells.

The Rituximab Consensus Expert Committee recommends obtaining a baseline IgG level before initiating rituximab for rheumatoid arthritis treatment and recommends measuring IgG levels before each rituximab